Shire PLC (ADR) (NASDAQ:SHPG) reported Q3 earnings and sales that exceeded analysts' expectations. SHPG is trading around the mid-point of the 52-week range between $121.57 and $264.98. The pharmaceutical company said non-GAAP diluted earnings rose 60% to $2.93 per American Depository Share, ahead of the Street consensus of $2.47 per share. Total revenue roe 32% to $1.6 billion, topping the $1.5 billion consensus estimate.For FY 2014, Shire PLC (ADR) (NASDAQ:SHPG) said it now expects to deliver non GAAP earnings per ADS growth "in the high 30%-range," up from the previous guidance for "low-to-mid 30% growth." It also said it expects product sales growth in the low 20%-range, up from previously "high teens growth." Reported net income rose to $479.7 million or $2.43 diluted earnings per ADS from $278.2 million or $1.46 a year ago.Myriad Genetics, Inc. (NASDAQ:MYGN) said it has established a Tumor BRACAnalysis CDx laboratory in Europe. Myriad's next-generation Tumor BRACAnalysis CDx test is a companion diagnostic that the company said will identify up to 50% more patients with BRAC mutations who may benefit from treatment with PARP inhibitors, such as olaparib, compared to conventional germline testing alone. Olaparib is a novel PARP inhibitor being developed by AstraZeneca (AZN). Earlier today, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization for olaparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy. Myriad Genetics, Inc. (NASDAQ:MYGN) trades in a 52-week range of $20.02 to $42.50. AZN shares trade in a 52-week rnage of $51.98 to $82.68, with share down 0.3% at $69.15.SunCoke Energy Inc (NYSE:SXC) reported mixed Q3 financial results Friday, with EPS beating Street estimates and revenues below the consensus of analysts polled by Capital IQ. Q3 income from continuing operations attributable to the company rose to $14.9 million, or $0.21 per diluted share, from $9.8 million, or $0.14 per diluted share. Analysts were expecting EPS of $0.09 per diluted share. The independent coke producer reported a net loss attributable to the company of $3.6 million in Q3, compared to net income of $6.2 million in the year-ago period. Q3 results reflect a loss related to discontinued operations of $18.5 million, or $0.26 per share. Q3 revenues fell to $367.6 million from $373.4 million, missing the consensus of $394 million.SunCoke Energy Inc (NYSE:SXC) also declared a quarterly cash dividend of $0.0585 per share, representing the first dividend to be paid to shareholders in SXC's history. SXC also provided FY2014 guidance, with domestic coke production expected at approximately 4.2 million tons, adjusted EBITDA from continuing operations attributable to the company of between $175 million-$192 million. The company expects to incur $10 million-$15 million of exit costs related with the sale and disposition of its coal mining business. Capital expenditures are expected to be $128 million, SXC said.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
